Agendia on Monday announced that six abstracts on its breast cancer tests will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place from December 6 to December 10.
All six studies focus on the impact of Agendia's MammaPrint and BluePrint tests and their ability to unveil the underlying biology of a breast cancer patient’s tumor to inform personalized treatment decisions, Agendia said.
MammaPrint is a 70-gene prognostic test that, combined with other clinicopathologic factors, determines a patient’s breast cancer recurrence risk, while BluePrint is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis, and potential response to systemic therapy, Agendia said.
Agendia said that three studies will showcase results from Agendia’s FLEX trial, a real-world evidence database of 10,000 patients with early-stage breast cancer that allowed researchers to conduct sub-studies in parallel to uncover new genomic trends.
The trial includes both genomic data and clinical data, allowing a critical focus on the needs of diverse, marginalized patient groups, the company said.
Data from the other three studies will help inform personalized treatment decisions, Agendia added. Two concern the utility of the MammaPrint test and one highlights data published in the Journal of Clinical Oncology supporting the gene expression profiling tests’ ability to inform the most effective treatment approaches for a woman’s unique cancer, regardless of age and menopausal status.